Purdue shells out a little more cash for a non-profit biotech working on naloxone OTC nasal spray
In the latest installment of the Purdue Pharma and opioid epidemic saga, the heavily sanctioned pharma company is shelling out a little more money — though not that much compared to the multi-billion dollar settlement it has reached. This time, it’s for $11 million — and the cash is going to a small-time biotech for an opioid overdose treatment drug.
The pharma announced the newest development recently into tiny biotech Harm Reduction Therapeutics (HRT), a 501c3 non-profit founded in 2017. The company’s sole focus is on getting an OTC nasal spray for naloxone approved and available on the market over the counter at “substantially lower retail cost,” compared to other naloxone products on the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.